Ignite Creation Date:
2024-07-17 @ 11:15 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06472076
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-18
Brief Title:
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 PD-L1 High Non-small-cell Lung Cancer NSCLC
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-10
Start Date Type:
ACTUAL
Primary Completion Date:
2028-09-19
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-09-19
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-18
First Submit QC Date:
None
Study First Post Date:
2024-06-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-18
Last Update Post Date:
2024-06-24
Last Update Post Date Type:
ACTUAL